[Mechanisms of tumor escape from immunologic response]. (Q52535965)

2 May 2018

review article

1 reference

title

[Mechanisms of tumor escape from immunologic response]. (English)

1 reference

2 May 2018

author

Régis T Costello

series ordinal

1

1 reference

2 May 2018

author name string

J A Gastaut

series ordinal

2

1 reference

2 May 2018

D Olive

series ordinal

3

1 reference

2 May 2018

language of work or name

French

0 references

publication date

1 July 1999

1 reference

2 May 2018

Revue de Médecine Interne

published in

1 reference

2 May 2018

volume

20

1 reference

2 May 2018

issue

7

1 reference

2 May 2018

page(s)

579-588

1 reference

2 May 2018

Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Deletions in the ligand for CD40 in X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1).

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Transplant immunosuppression-related malignant lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Epstein-Barr virus infections in males with the X-linked lymphoproliferative syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Paraneoplastic syndromes: a brief review

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Vitiligo and cutaneous melanoma. A case study

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Vitiligo in patients with metastatic melanoma: a good prognostic sign

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Paraneoplastic night blindness with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Cutaneous melanoma-associated retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Paraneoplastic retinopathy in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Melanoma-associated retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Prognostic value of follicular dendritic cells in nodular sclerosing Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

[Chronic myeloid leukemia, biological aspects]

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

T cell defined tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Molecular characterization of defective antigen processing in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Identification of human cancers deficient in antigen processing

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Defective Major Histocompatibility Complex Class I Expression in a Sarcomatoid Renal Cell Carcinoma Cell Line

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Loss of HLA class-I alleles, heavy chains and β2-microglobulin in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

B7-mediated costimulation and the immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

CD28 and T-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumo

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Fas ligand in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Downregulation of Fas ligand by shedding

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

The CD40 antigen and its ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Acquired CD40-ligand deficiency in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Cytokines, tumour-cell death and immunogenicity: a question of choice

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

In search of the 'missing self': MHC molecules and NK cell recognition

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Antibody-based immunological therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Aberrant expression of HLA class-I antigens in Burkitt lymphoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Dendritic cells: potential role in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Induction of B cell costimulatory function by recombinant murine CD40 ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

A novel function of CD40: induction of cell death in transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Different apoptotic pathways mediated by Fas and the tumor-necrosis-factor receptor. Cytosolic phospholipase A2 is not involved in Fas-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

Apoptosis by death factor

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2899%2980107-6

7 January 2021

10.1016/S0248-8663(99)80107-6

Identifiers

DOI

1 reference

2 May 2018

1 reference

2 May 2018